316 related articles for article (PubMed ID: 10334346)
1. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group.
Am J Ophthalmol; 1999 May; 127(5):537-44. PubMed ID: 10334346
[TBL] [Abstract][Full Text] [Related]
2. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1.
Stewart R; Horwitz B; Howes J; Novack GD; Hart K
J Cataract Refract Surg; 1998 Nov; 24(11):1480-9. PubMed ID: 9818338
[TBL] [Abstract][Full Text] [Related]
3. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery.
Lane SS; Holland EJ
J Cataract Refract Surg; 2013 Feb; 39(2):168-73. PubMed ID: 23232255
[TBL] [Abstract][Full Text] [Related]
4. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2.
Ophthalmology; 1998 Sep; 105(9):1780-6. PubMed ID: 9754192
[TBL] [Abstract][Full Text] [Related]
5. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study.
Holzer MP; Solomon KD; Sandoval HP; Vroman DT
J Cataract Refract Surg; 2002 Jan; 28(1):93-9. PubMed ID: 11777716
[TBL] [Abstract][Full Text] [Related]
6. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I.
Friedlaender MH; Howes J
Am J Ophthalmol; 1997 Apr; 123(4):455-64. PubMed ID: 9124242
[TBL] [Abstract][Full Text] [Related]
7. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group.
Dell SJ; Shulman DG; Lowry GM; Howes J
Am J Ophthalmol; 1997 Jun; 123(6):791-7. PubMed ID: 9535623
[TBL] [Abstract][Full Text] [Related]
8. Change in intraocular pressure during long-term use of loteprednol etabonate.
Novack GD; Howes J; Crockett RS; Sherwood MB
J Glaucoma; 1998 Aug; 7(4):266-9. PubMed ID: 9713785
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation.
Holland EJ; Djalilian AR; Sanderson JP
Cornea; 2009 Dec; 28(10):1139-43. PubMed ID: 19770719
[TBL] [Abstract][Full Text] [Related]
10. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis.
Asbell P; Howes J
CLAO J; 1997 Jan; 23(1):31-6. PubMed ID: 9001768
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of 1% rimexolone versus 1% prednisolone acetate in the treatment of anterior uveitis--a randomized triple masked study.
Biswas J; Ganeshbabu TM; Raghavendran SR; Raizada S; Mondkar SV; Madhavan HN
Int Ophthalmol; 2004 May; 25(3):147-53. PubMed ID: 15847313
[TBL] [Abstract][Full Text] [Related]
12. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
Abelson M; Howes J; George M
J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery.
Rajpal RK; Roel L; Siou-Mermet R; Erb T
J Cataract Refract Surg; 2013 Feb; 39(2):158-67. PubMed ID: 23218817
[TBL] [Abstract][Full Text] [Related]
14. Loteprednol Etabonate 0.5% Gel Vs. Prednisolone Acetate 1% Solution After Descemet Membrane Endothelial Keratoplasty: Prospective Randomized Trial.
Price MO; Feng MT; Scanameo A; Price FW
Cornea; 2015 Aug; 34(8):853-8. PubMed ID: 26020827
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
Berdy GJ; Stoppel JO; Epstein AB
Clin Ther; 2002 Jun; 24(6):918-29. PubMed ID: 12117082
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis.
Dell SJ; Lowry GM; Northcutt JA; Howes J; Novack GD; Hart K
J Allergy Clin Immunol; 1998 Aug; 102(2):251-5. PubMed ID: 9723669
[TBL] [Abstract][Full Text] [Related]
17. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use.
Amon M; Busin M
Int Ophthalmol; 2012 Oct; 32(5):507-17. PubMed ID: 22707339
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.
Shulman DG; Lothringer LL; Rubin JM; Briggs RB; Howes J; Novack GD; Hart K
Ophthalmology; 1999 Feb; 106(2):362-9. PubMed ID: 9951491
[TBL] [Abstract][Full Text] [Related]
19. Intraocular pressure response to loteprednol etabonate in known steroid responders.
Bartlett JD; Horwitz B; Laibovitz R; Howes JF
J Ocul Pharmacol; 1993; 9(2):157-65. PubMed ID: 8345288
[TBL] [Abstract][Full Text] [Related]
20. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review.
Rajpal RK; Digby D; D'Aversa G; Mah F; Hollander DA; Conway T
J Ocul Pharmacol Ther; 2011 Jun; 27(3):305-8. PubMed ID: 21574815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
